Literature DB >> 23534951

Updated role of nitric oxide in disorders of erythrocyte function.

Marc J Kahn1, Jason H Maley, George F Lasker, Philip J Kadowitz.   

Abstract

Nitric oxide is a potent vasodilator that plays a critical role in disorders of erythrocyte function. Sickle cell disease, paroxysmal nocturnal hemoglobinuria and banked blood preservation are three conditions where nitric oxide is intimately related to dysfunctional erythrocytes. These conditions are accompanied by hemolysis, thrombosis and vasoocclusion. Our understanding of the interaction between nitric oxide, hemoglobin, and the vasculature is constantly evolving, and by defining this role we can better direct trials aimed at improving the treatments of disorders of erythrocyte function. Here we briefly discuss nitric oxide's interaction with hemoglobin through the hypothesis regarding Snitrosohemoglobin, deoxyhemoglobin, and myoglobin as nitrite reductases. We then review the current understanding of the role of nitric oxide in sickle cell disease, paroxysmal nocturnal hemoglobinuria, and banked blood, and discuss therapeutics in development to target nitric oxide in the treatment of some of these disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23534951      PMCID: PMC3635483          DOI: 10.2174/1871529x11313010009

Source DB:  PubMed          Journal:  Cardiovasc Hematol Disord Drug Targets        ISSN: 1871-529X


  44 in total

Review 1.  Vascular effects of the red blood cell storage lesion.

Authors:  John D Roback
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion.

Authors:  Chenell Donadee; Nicolaas J H Raat; Tamir Kanias; Jesús Tejero; Janet S Lee; Eric E Kelley; Xuejun Zhao; Chen Liu; Hannah Reynolds; Ivan Azarov; Sheila Frizzell; E Michael Meyer; Albert D Donnenberg; Lirong Qu; Darrel Triulzi; Daniel B Kim-Shapiro; Mark T Gladwin
Journal:  Circulation       Date:  2011-07-11       Impact factor: 29.690

3.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

Authors:  Mark T Gladwin; Gregory J Kato; Debra Weiner; Onyinye C Onyekwere; Carlton Dampier; Lewis Hsu; R Ward Hagar; Thomas Howard; Rachelle Nuss; Maureen M Okam; Carole K Tremonti; Brian Berman; Anthony Villella; Lakshmanan Krishnamurti; Sophie Lanzkron; Oswaldo Castro; Victor R Gordeuk; Wynona A Coles; Marlene Peters-Lawrence; James Nichols; Mary K Hall; Mariana Hildesheim; William C Blackwelder; James Baldassarre; James F Casella
Journal:  JAMA       Date:  2011-03-02       Impact factor: 56.272

4.  Pulmonary hypertension in lambs transfused with stored blood is prevented by breathing nitric oxide.

Authors:  David M Baron; Binglan Yu; Chong Lei; Aranya Bagchi; Arkadi Beloiartsev; Christopher P Stowell; Andrea U Steinbicker; Rajeev Malhotra; Kenneth D Bloch; Warren M Zapol
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

5.  Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7).

Authors:  M E Steiner; S F Assmann; J H Levy; J Marshall; S Pulkrabek; S R Sloan; D Triulzi; C P Stowell
Journal:  Transfus Apher Sci       Date:  2010-07-23       Impact factor: 1.764

6.  Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron.

Authors:  Eldad A Hod; Gary M Brittenham; Genia B Billote; Richard O Francis; Yelena Z Ginzburg; Jeanne E Hendrickson; Jeffrey Jhang; Joseph Schwartz; Shruti Sharma; Sujit Sheth; Anthony N Sireci; Hannah L Stephens; Brie A Stotler; Boguslaw S Wojczyk; James C Zimring; Steven L Spitalnik
Journal:  Blood       Date:  2011-10-20       Impact factor: 22.113

Review 7.  Nitric oxide and disorders of the erythrocyte: emerging roles and therapeutic targets.

Authors:  Jason H Maley; George F Lasker; Philip J Kadowitz
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-12-01

8.  Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis.

Authors:  C Alvin Head; Paul Swerdlow; William A McDade; Ratan Mani Joshi; Tohru Ikuta; Melanie L Cooper; James R Eckman
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 10.  No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing.

Authors:  Achim Schmidtko; Irmgard Tegeder; Gerd Geisslinger
Journal:  Trends Neurosci       Date:  2009-05-04       Impact factor: 13.837

View more
  4 in total

1.  Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease.

Authors:  Rana T Alhashimi; Mohini S Ghatge; Akua K Donkor; Tanvi M Deshpande; Nancy Anabaraonye; Dina Alramadhani; Richmond Danso-Danquah; Boshi Huang; Yan Zhang; Faik N Musayev; Osheiza Abdulmalik; Martin K Safo
Journal:  Biomolecules       Date:  2022-05-12

Review 2.  Triggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte death.

Authors:  Elisabeth Lang; Florian Lang
Journal:  Biomed Res Int       Date:  2015-03-04       Impact factor: 3.411

3.  Short-term treatment with nitrate is not sufficient to induce in vivo antithrombotic effects in rats and mice.

Authors:  K Kramkowski; A Leszczynska; K Przyborowski; B Proniewski; N Marcinczyk; U Rykaczewska; D Jarmoc; E Chabielska; S Chlopicki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-10-14       Impact factor: 3.000

4.  Redox regulation of nitrosyl-hemoglobin in human erythrocytes.

Authors:  Flavia Dei Zotti; Roxane Verdoy; Davide Brusa; Irina I Lobysheva; Jean-Luc Balligand
Journal:  Redox Biol       Date:  2019-12-05       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.